GlobeNewswire by notified

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder)


The event will take place on Thursday, 6 June 2024 at Coloplast’s Headquarters
Holtedam 3, 3050 Humlebaek, Denmark
from 11.30 - 18.00 CEST (Central European Summer Time)

Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.
The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.
The purpose of the event is to provide participants with the opportunity to meet Coloplast’s Executive Management and other members of senior management.
The day will start with a plenary session, covering a brief presentation of our H1 2023/24 results, an update on our Strive25 strategy and a dedicated session on the recent acquisition of Kerecis. In the afternoon, participants will be split into groups and rotate between four Q&A breakout sessions. Participation in the breakout sessions will be in-person only.
The formal program will end at 18.00, followed by an opportunity to meet the Coloplast management team in an informal setting.

Agenda in CEST
11.00 - 11.30 Registration
11.30 - 13.00 Plenary session: H1 2023/24 results, Strive25 strategy update, Kerecis
13.00 - 13.50 Lunch break
13.50 - 18.00 Q&A breakout sessions (incl. breaks)
18.00 - 19.30 BBQ and drinks (on premise)

Coloplast representatives

Plenary session
Kristian Villumsen, President and CEO
Anders Lonning-Skovgaard, Executive Vice President and CFO
Fertram Sigurjonsson, Founder and CEO of Kerecis

Breakout sessions
- Innovation
Nicolai Buhl Andersen, Executive Vice President, Innovation
Anders Nørby, Senior Vice President, R&D
Steen Blaabjerg Morvan, Senior Vice President, Marketing & Services
Marie Smidt, Vice President, Bowel Management
- Growth
Paul Marcun, Executive Vice President, Growth
Manu Varma, Senior Vice President, North America Chronic Care
Johan Mastrell, Senior Vice President, Region UKI Chronic Care
- Interventional Urology, Voice & Respiratory Care and Adv. Wound Dressings
Thomas NP Johns Jr, Senior Vice President, Interventional Urology
Caroline Vagner Rosenstand, Senior Vice President, Voice & Respiratory Care
Jesper Johnsen Steen, Senior Vice President, Wound and Skin Care
- Global Operations, Sustainability and People & Culture
Allan Rasmussen, Executive Vice President, Global Operations
Camilla Hjort Pagh, Senior Vice President, Global QA, RA & Sustainability
Dorthe Rønnau, Senior Vice President, People & Culture 

In-person participation

If you wish to join us in person and attend the plenary session and the Q&A breakout sessions, please register by sending an email to stating your full name, company, contact phone number and itinerary (if relevant).
Kindly register before Friday, 17 May 2024.

Virtual participation
Virtual participation will be possible for the plenary session.
A link for the webcast of the plenary sessions will be available on our website closer to the date.

For more information, please contact:

Aleksandra Dimovska, Sr. Director, IR
Direct tel.: +45 4911 2458

Kristine Husted Munk, Sr. IR Manager
Direct tel.: +45 4911 3266

Hannah Larsen, IR Coordinator
Direct tel.: +45 4911 3616


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued


Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye